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Abstract
Many retrospective and prospective studies have been performed to understand the emergence and dissemination of 
antibiotic-resistant microorganisms. The rates of antimicrobial drug resistance among bacterial pathogens are high 
and now represent a worldwide concern, both in human medicine and veterinary practices. The aim of this review is to 
describe the mechanisms of antibiotic resistance and the risks associated with antimicrobial use in animal production. 
Pathogens with major impacts on human and animal health are discussed, including multidrug-resistant and extensi-
vely drug-resistant Gram-negative and Gram-positive bacteria. 
Keywords: Bacterial resistance. Growth promoters. Public health. 
Resumo
Vários estudos retrospectivos e prospectivos têm sido realizados para investigar o aumento e a disseminação de micro-
organismos resistentes a antimicrobianos. As taxas de resistência entre esses agentes são crescentes e representam uma 
preocupação mundial, tanto em medicina humana como em veterinária. O objetivo da presente revisão é descrever os 
mecanismos de resistência antimicrobiana e os riscos associados ao uso de antimicrobianos na produção animal. Os 
patógenos de maior impacto em saúde humana e animal são abordados, incluindo bactérias Gram-negativas e Gram-
positivas multirresistentes e extensivamente resistentes.
Palavras-chave: Resistência bacteriana. Promotores de crescimento. Saúde pública.
Antibiotics have been sold like sweets (GILBERT, 
2012). Since the discovery of penicillin, which 
revolutionized the treatment of infectious diseases 
in the past century, antimicrobial agents have been 
broadly used worldwide, and many countries do not 
have legislation to control antibiotic consumption. 
Currently, the prevalence of antimicrobial- 
resistant pathogens has increased at a speed inversely 
proportional to the approval of new drugs. Thus, 
in regard to infectious diseases, the emergence of 
resistance is one of the top health challenges in the 
21st century, especially in hospital settings. However, 
when considering veterinary medicine, although 
the amount of antibiotics consumed in livestock is 
almost double the amount used by humans, the 
Correspondence to:
Andrea Micke Moreno
Faculdade de Medicina Veterinária  
e Zootecnia da Universidade de São Paulo (USP)
Av. Prof. Dr. Orlando Marques de Paiva, 87, Cidade Universitária
05508-270, São Paulo, SP, Brazil
Phone + 5502111 3091-1377, Fax: +5502111 3091-7928
e-mail: morenoam@usp.br
Received: 17/06/2013
Aproved: 01/08/2013
role of veterinary antimicrobials use in resistance 
development has only recently been discussed 
(PHILLIPS et al., 2004; AARESTRUP, 2012). In this 
context, foodborne pathogens and urinary tract 
infection-related agents deserve special attention due 
to the potential of transmission through consumption or 
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manipulation of animal-origin food (NORDSTROM; 
LIU; PRICE, 2013). In this context, the surveillance 
of resistant strains in Brazilian farms is extremely 
important because this country is one of the biggest 
animal food producers in the world. 
Mechanisms of resistance
Bacteria can evade the actions of antibiotics using 
diverse mechanisms. Such antibiotic resistance may 
be either intrinsic or acquired. Intrinsic resistance 
is inherent to all specimens of the species. In 
such cases, in general, the gene that encodes the 
intrinsic resistance is chromosomal. For example, all 
Gram-negative bacteria are naturally resistant to 
vancomycin due to their cell wall structure, which 
differs from Gram-positive cell walls (MADIGAN 
et al., 2012). However, acquired resistance involves 
a change in the organism’s genetic composition via 
either mutation in the chromosomal DNA or the 
acquisition of exogenous DNA. Mutations occur 
randomly at a low frequency, and the mutations can 
sometimes result in advantageous characteristics that 
can be selected. For example, mutation accumulation 
in quinolone targets in DNA gyrase is the main 
mechanism against quinolone binding (JACOBY, 
2005). Though bacteria can acquire external DNA by 
bacteriophage infection and transformation, plasmid 
mobilization by direct cell-to-cell contact, also termed 
conjugation, is the most common transfer mechanism 
of antimicrobial resistance-encoding genes.
The main resistance mechanisms are efflux pumps, 
permeability reduction, antibiotic target modification 
and antibiotic inactivation (BARIE, 2012). Efflux 
pumps decrease cellular drug accumulation because 
compounds are pumped out of the inner membrane 
to the periplasmic space or directly to the external 
medium (HORIYAMA; YAMAGUCHI; NISHINO, 
2010). Some efflux pumps are capable of extruding 
many compounds, including detergents and different 
antimicrobial classes. In this context, in Gram-
negative bacteria, the resistance-nodulation-division 
(RND) family forms a protein tripartite complex 
with the inner membrane, periplasmic space and 
outer membrane, forming an efficient channel to 
extrude compounds (HORIYAMA; YAMAGUCHI; 
NISHINO, 2010; ALVAREZ-ORTEGA; OLIVARES; 
MARTÍNEZ, 2013). In contrast, in Gram-positive 
bacteria, the main multidrug efflux pumps belong 
to the multidrug and toxic compound extrusion 
(MATE) family (ALVAREZ-ORTEGA; OLIVARES; 
MARTÍNEZ, 2013). 
In addition to efflux pumps, porin loss can confer 
resistance to a range of antimicrobials. Porins are 
nonspecific diffusion channels in the outer membrane 
that permit the influx of small hydrophilic agents, 
including antibiotic molecules. Thus, non-functional 
porin production or gene repression that results in 
porin loss decreases the membrane permeability, 
resulting in antimicrobial resistance (NIKAIDO; 
PAGÉS, 2012). 
Regarding antibiotic target modification, 
accumulations of mutations in DNA gyrase and 
DNA topoisomerase IV have been reported as the 
main mechanisms of resistance to quinolones, as 
these mutations can result in enzymes being unable 
to bind to quinolones due to structural modification. 
Penicillin-binding proteins (PBPs) are cell wall-
synthesizing enzyme targets for beta-lactams. Alterations 
in PBP confer penicillin resistance. For example, 
methicillin-resistant Staphylococcus aureus produces 
PBP 2a, which is incapable of binding methicillin 
(GEORGOPAPADAKOU, 1993). 
Although all resistance mechanisms deserve attention, 
antibiotic inactivation has been described as a main 
global problem in health care units and communities. 
Bacteria may produce enzymes that modify or 
destroy antimicrobial chemical structures, which 
results in ineffectiveness. Phosphotransferases, 
acetyltransferases and adenyltransferases chemically 
modify aminoglycosides, which interferes with either 
drug transport or the binding of the drug at the site 
of antibacterial action, the 30S ribosomal subunit 
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(WRIGHT, 1999). Recently, an aac6Ib variant, aac6Ib-
cr, was identified that encodes an acetyltransferase 
that inactivates quinolones (ROBICSEK et al., 2005). 
Many commercialized antimicrobials belong to the 
beta-lactam class; due to rapid spread, beta lactamases 
became the most important inactivating antimicrobial 
enzymes. 
Some bacteria, mostly Enterobacteriaceae, Staphy-
lococcus spp., Enterococcus spp. and Pseudomonas 
aeruginosa, become more readily resistant to 
certain antibiotic categories than others, such as 
Clostridium spp. and Streptococcus spp., which are 
still fully susceptible to penicillin G (BOGAARD; 
STOBBERINGH, 2000; MAGIORKAS et al., 2012). 
Recently, a group of international experts from the 
Centers for Disease Control and Prevention (CDC) 
and the European Centre for Disease Prevention and 
Control (ECDC) created a standardized international 
terminology with which to describe acquired resistance 
profiles in healthcare-associated microorganisms and 
published lists of antibiotics for susceptibility tests. 
According to the standard definitions, multidrug-
resistant was defined as acquired non-susceptibility 
to at least one agent in three or more antimicrobial 
categories, whereas extensively drug-resistant was 
defined as non-susceptibility to at least one agent in 
all but two or fewer antimicrobial categories (i.e., the 
bacterial isolates remain susceptible to only one or two 
categories). Strains non-susceptible to all agents in all 
antimicrobial categories are classified as pandrug-
resistant bacteria (MAGIORAKOS et al., 2011). 
Antimicrobial use in animal production 
Following penicillin use as a human therapeutic 
agent, the advantages of antibiotics were soon 
thereafter applied in veterinary medicine and 
agriculture, including food animal production, 
pets and aquaculture (TEUBER, 1999, 2001). The 
extensive use and misuse in all settings has created 
strong selection pressure, which has resulted in the 
survival and persistence of resistant strains. 
In veterinary medicine, substances exhibiting 
antimicrobial activity are extensively used in animals 
for therapy, prophylaxis, metaphylaxis and growth 
promotion (MARSHALL; LEVY, 2011). Therapeutic 
use is the administration of an antimicrobial to an 
animal or group of animals that exhibit frank clinical 
disease. In farms, individual treatment is often 
impractical, particularly in food-producing animals, 
which are kept in larger groups. 
Usually, antimicrobials in such large animal 
groups are administered when single animals of the 
group present with symptoms of the disease, as it is 
expected that most of the group will become affected. 
Prevention/prophylaxis is the administration of an 
antimicrobial to exposed healthy animals considered 
to be at risk before expected onset of disease and for 
which no etiological agent has yet been cultured. 
Metaphylaxis is a term sometimes used when there 
is clinical disease in some animals, but all are treated 
with the aim of reducing the numbers of sick and/or 
dead animals (PHILLIPS et al., 2004). 
Growth promotion is the administration of an 
antimicrobial, usually as a feed additive, over a period 
of time to growing animals that results in improved 
physiological performance. At least four mechanisms 
have been proposed as explanations of antibiotic-
mediated growth enhancement: the inhibition of sub-
clinical infections, the reduction of growth-depressing 
microbial metabolites, the reduction of microbial 
use of nutrients and the enhanced uptake and use of 
nutrients through the thinner (PHILLIPS et al., 2004).
In this context, the amount of antibiotics consumed 
in livestock is almost double that used by humans. 
This is an important reason for the emergence of 
intestinal resistant bacteria and, due to the similarities 
between veterinary and human antimicrobials, has 
led to cross-resistance (MARSHALL; LEVY, 2011). In 
other words, the same resistance mechanism confers 
resistance to veterinary and human antibiotics. For 
example, CTX-M beta-lactamase production leads 
to resistance to both ceftiofur (veterinary use) and 
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cefotaxime (human use) cephalosporins. Thus, the 
food animal gut may become a reservoir of resistance 
genetic determinants. 
Farm and slaughterhouse workers, including 
veterinarians, have a high risk of being colonized 
or infected with resistant bacteria via direct contact 
with infected or colonized food animals and derived 
products (GARCIA-ALVAREZ et al., 2012). Moreover, 
occupational workers and their families provide a 
conduit for the entry of resistance determinants into 
community, hospital and environmental settings. These 
genes may potentially be transmitted to pathogens, 
as bacteria are capable of acquiring exogenous DNA 
(PHILLIPS et al., 2004; MARSHALL; LEVY, 2011). 
Indirect transmission via the animal production 
chain can occur through food consumption and 
manipulation. Moreover, the resistance genes may 
be horizontally transferred to indigenous intestinal 
microflora and pathogens, resulting in therapeutic 
failure in potential endogenous infections. Figure 
1, adapted from Phillips et al. (2004), describes 
the possible pathways and routes of transmission 
of gastrointestinal pathogens and bacteria from 
microbiota between animals (wild animals, pets and 
food animals) and humans. Considering these routes, 
antimicrobial-resistant bacteria can be transmitted 
between animals and humans and vice versa.
As a precaution, European Union member states 
banned some growth promoters after the emergence 
of vancomycin-resistant enterococci (VRE), based on 
the hypothesis of selection of VRE in the intestinal 
flora of poultry and pigs and due to the use of avoparcin 
as a feed additive (BOGAARD; STOBBERINGH, 
2000). In Europe, colonization with VRE occurs in 
the community, whereas in the United States, such 
colonization has been demonstrated only in hospital 
settings. As a result of some epidemiological studies, 
the use of avoparcin at subtherapeutic levels was 
banned by Denmark in 1995, followed by Germany in 
1996 and, subsequently, the entire European Union. 
Bans on using bacitracin zinc, spiramycin, tylosin and 
virginiamycin in animal feed became effective for the 
15 member states of the European Union on July 1, 
1999 (TOLLEFSON; MILLER, 2000). The group of 
antimicrobials that can be used as growth promoters 
in animal production in Brazil is presented in Table 1. 
The literature on cross-resistance induced by growth 
promoters is very controversial, and the impact of 
the ban in Europe remains under discussion because 
it might even have adverse effects on human health. 
There is epidemiological evidence that the growth-
promoters ban had a marked effect, with decreased 
VRE rates in the fecal flora of man and animals. 
Although there was an overall 50% decrease in the total 
Figure 1 -  Possible pathways and routes of transmission of gastrointestinal pathogens and bacteria from microbiota be-
tween animals (wild animals, pets and food animals) and humans 
 Fonte: Adapted from Phillips et al. (2004).
175
Braz. J. Vet. Res. Anim. Sci., São Paulo, v. 50, n. 3, p. 171-183, 2013
number of kilograms of antibiotic used as feed animal 
additive, the therapeutic use of some drugs increased 
extensively. The emergence of some gastrointestinal 
problems, as clostridial necrotic enteritis in poultry 
and Lawsonia intracellularis infections in pigs, has 
been associated with bacitracin withdrawal. The 
increase in the incidence of food-borne pathogens, as 
Campylobacter and Salmonella, after antibiotic bans is 
now a human health concern (PHILLIPS et al., 2004).
Bacteria and mechanisms of major  
impact in human health
Gram-negative bacteria
For Gram-negative bacteria, beta-lactamase produc- 
tion has been identified as the most important problem 
in bacterial infection management (HAWKEY; 
JONES, 2013). 
Beta-lactamase production is the most common 
mechanism associated with beta-lactam resistance, 
including resistance to penicillins, cephamycins, 
monobactams, cephalosporins and carbapenems, 
which is clinically significant for treating Gram-
Table 1 - Antimicrobials with authorized use in feed as animals grow promoters in Brazil 
Antimicrobial Animal specie 
Avilamycin Broiler, turkey, swine 
Bacitracin methylene disalicilato Broiler, laying hen, turkey, swine
Bacitracin Zinc Broiler, laying hen, turkey, quail, swine, bovine 
Colistin sulphate Broiler, laying hen, swine, bovine 
Chlorhexidine hydrochloride Broiler, laying hen, swine
Enramycin  Broiler, laying hen, swine, bovine 
Erythromycin  Swine
Spiramycin  Broiler, swine, calf 
Flavomycin  Broiler, swine, rabbit, bovine 
Halquinol Broiler, laying hen, swine,
Lasalocid  Bovine
Lincomycin  Broiler, swine
Monensin  Bovine, ovine
Salinomycin  sodium  Swine, bovine
Tiamulin  Swine
Tilosina  Broiler, laying hen, swine
Virginiamycin  Broiler, turkey, swine, bovine
negative bacterial infections (BUSH, 2013). There are 
two classification schemes for the multiplicity and 
diversity of beta-lactamases. The Ambler’s scheme 
groups beta-lactamases into the A, B, C and D classes 
according to conserved and distinguishing amino 
acid motifs (AMBLER, 1980). Originally, Ambler 
subdivided beta-lactamases that were active-site 
serine beta-lactamases and metallo-beta-lactamases, 
which require a bivalent metal ion for activity, into the 
A and B classes, respectively. AmpC beta-lactamases 
were later grouped into the C class, and OXA-type 
enzymes, in general, were included in the D class 
(BUSH; JACOBY; 2010). In contrast, the Bush-Jacoby-
Medeiros system classifies beta-lactamases according 
to their functional characteristics (substrates and 
inhibitors) (Table 2). The Lahey Clinic maintains a 
website with beta-lactamase classifications and amino 
acid sequences for TEM, SHV and OXA extended-
spectrum and inhibitor-resistant enzymes and other 
enzymes with clinical significance (BUSH; JACOBY, 
2013). At present, there are a large number of 
described enzymes. In most cases, plasmids harboring 
beta lactamase-encoding genes are responsible for the 
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Table 2 - Beta-lactamases classification according to Bush-Jacoby-Medeiros
 Molecular class Distinctive                                     Inhibited by:                   Representative 
Bush-Jacoby group (Ambler’s scheme) substrate(s)               Enzyme(s)
   Clavulanic acid EDTA
1 C Cephalosporins - - E. coli AmpC, P99, ACT-1, 
CMY-2, FOX-1, MIR-1 
1e C Cephalosporins - - GC1, CMY-37
2a A Penicillins + - PC-1
2b A Penicillins, early cephalosporins + - TEM-1, TEM-2, SHV-1
2be A Extended-spectrum cephalosporins, monobactams + - TEM-3, SHV-2, CTX-
M-15, PER-1, VEB-1
2br A Penicillins - - TEM-30, SHV-10 
2ber A Extended-spectrum cephalosporins, monobactams - - TEM-50
2c A Carbenicillin + - PSE-1, CARB-3
2ce A Carbenicillin, cefepime + - RTG-4
2d D Cloxacillin Variable - OXA-1, OXA-10
2de D Extended-spectrum cephalosporins Variable - OXA-11, OXA-15
2df D Carbapenems Variable - OXA-23, OXA-48
2e A Extended-spectrum cephalosporins + - CepA
2f A Carbapenems Variable - KPC-2, IMI-1, SME-1
3a B(B1) Carbapenems - + IMP-1, VIM-1, CerA, IND-1
3b B(B2) Carbapenems - + CphA, Sfh-1
Source: Bush et al. (2010).
rapid spread of these enzymes and the high emergence 
rates of resistant phenotypes.
 The extended-spectrum beta-lactamases (ESBLs), 
which hydrolyze the third- and fourth- generation 
cephalosporins, are included in Ambler’s class A. 
These enzymes are sensitive to competitive inhibitors 
such as clavulanic acid, tazobactam and sulbactam. 
AmpC beta-lactamases hydrolyze cephamycins, 
such as cefoxitin, and belong to class C according to 
Ambler’s scheme (BARIE, 2012). 
Carbapenems (imipenem, ertapenem and meropenem) 
are the more effective beta-lactams available against 
Gram-negative bacilli. The carbapenemases are 
widely described among Klebsiella pneumoniae, 
Pseudomonas aeruginosa and Acinetobacter baumannii 
strains, mainly in health care units. Some studies have 
described high mortality due to infections with resistant 
strains. Carbapenem-resistant phenotypes among non-
fermentative bacteria have been reported globally due to 
KPC (Klebsiella pneumoniae carbapenemase), metallo-
beta-lactamase and OXA-type enzyme production. In 
Brazil, outbreaks caused by carbapenemase producers 
are frequently reported in hospital intensive care units 
(ICUs) (ROSSI, 2011). 
In Brazil, the most commonly beta-lactamases 
identified in the food animal production chain 
belongs to class A according Ambler’s scheme, 
which groups the SHV, TEM and CTX-M ESBLs. 
It is speculated that wide use of ceftiofur on animal 
farms have contributed to the emergence of ESBL 
producers in livestock. In Brazil, extended-spectrum 
cephalosporin-resistant strains on animal farms have 
been described for many years (CORTEZ et al., 2006). 
Salmonella enterica
Salmonella enterica have assumed epidemiological 
importance due the large number of outbreaks and 
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infections caused by contaminated water and food 
consumption. Although most salmonellosis cases 
result in self-limited gastroenteritis and do not require 
antimicrobial therapy, severe infections can occur in 
patients of extreme ages, both neonates and elderly, 
and the immunocompromised. In Brazil, Salmonella 
enterica has been reported as the main bacterial agent 
associated with foodborne diseases. According to 
the Secretaria de Vigilância em Saúde, from 1999 to 
2008, 1275 Salmonella enterica outbreaks occurred 
in Brazil, corresponding to 42.9% of total foodborne 
outbreaks (BRASIL, 2009). In Rio Grande do Sul 
state, 74 of the 99 total foodborne outbreaks reported 
in the year 2000 were caused by Salmonella enterica 
(NADVORNY; FIGUEIREIDO; SHIMIDT, 2004). 
Resistances to tetracyclines, aminoglycosides 
and sulfonamides have been frequently described 
(FONSECA et al., 2006; PEIRANO et al., 2006; 
MICHAEL; CARDOSO; SCHWARZ, 2008; VAZ et al., 
2010; RIBEIRO et al., 2011); however, in contrast to 
other Enterobacteriaceae, such as Escherichia coli and 
Klebsiella pneumoniae, ESBL-producing Salmonella 
enterica reports are still rare in Brazil. In 2004, Mulvey 
et al. reported a Salmonella Agona OXA-type beta-
lactamase producer isolated in 1996 from a hospitalized 
patient. Peirano et al. (2006) conducted a study 
including Salmonella strains isolated from humans, 
animal feed, food-producing animals, foodstuffs and 
other sources regarding antimicrobial resistance, and 
they identified CTX-M-8 and CTX-M-9 type ESBL-
producers without specifying the origin (human 
or animal). Recently, clonally unrelated Salmonella 
Typhimurium carrying CTX-M-2-encoding genes has 
been reported in isolates from the poultry production 
chains in Sao Paulo and Porto Alegre (FERNANDES 
et al., 2009), and Silva et al. (2013) confirmed that the 
blaCTX-M-2 gene spread among the S. Schwarzengrund 
and S. Agona serotypes on poultry farms from the 
Southern region of Brazil. Thus, the dissemination of 
multiresistant phenotypes in animal production has 
been increasing among Salmonella strains. 
Klebsiella pneumoniae 
Klebsiella pneumoniae isolates carrying ESBL 
genes are endemic in Brazil. According to Rossi 
(2011), approximately 40-50% of K. pneumoniae 
isolates produce ESBL-type beta-lactamases. The 
constant isolation of ESBL-producing strains and 
the risk of treatment failure with cephalosporins 
have led to increased use of carbapenems; 
consequently, carbapenem-resistant phenotypes 
have been disseminated. The carbapenem resistance 
in K. pneumoniae strains can arise by the loss or 
modification of porins, which is associated with 
the production of metallo-beta-lactamases (MBLs) 
and non-metallo-carbapenemases (KPC, GES or 
OXA types); this type of resistance is associated 
with high mortality rates (GARCÍA-FERNÁNDEZ 
et al., 2012). Klebsiella pneumoniae carbapenemase 
(KPC) is an active-site serine enzyme that hydrolyzes 
carbapenems and extended-spectrum cephalosporins 
and is disseminated worldwide. The first KPC-
producing K. pneumoniae strain was isolated in 2006 
in Recife (Northeastern of Brazil) and was found 
to harbor blaCTX-M-2, blaTEM-1 and blaSHV-11 additional 
beta lactamase-encoding genes (ROSSI, 2011). KPC 
enzymes enable resistance to cephalosporins and 
carbapenems, are endemic in Brazilian ICUs and 
represent a serious challenge regarding bacterial 
infections (ANDRADE, 2011). Infections due to 
KPC producers are usually treated with colistin 
and/or tigecycline. However, tigecycline use is not 
recommended for bloodstream infections. 
Escherichia coli
TEM- and SHV-type beta-lactamases are endemic in 
developed countries, but in South America, including 
Brazil, CTX-M-type is the prevalent ESBL. The first 
report of the CTX-M group occurred a Proteus mirabilis 
strain with a cephalosporin-resistant phenotype 
isolated from a patient in 2000 (BONNET et al., 2000). 
Later, in 2007, the first community-origin Escherichia 
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coli isolate that produced CTX-M-2 was reported 
(MINARINI et al., 2007). In the same year, a European 
study identified the blaCTX-M-2 gene in E. coli 
isolated from poultry imported from Brazilian farms 
(WARREN et al., 2008). According to literature reports, 
CTX-M-2 group bacteria are endemic in Brazil among 
Enterobacteriaceae isolates and have been described 
in many states (São Paulo, Rio de Janeiro, Minas 
Gerais, Santa Catarina, Rio Grande do Sul) (SILVA; 
LINCOPAN, 2012). Thus, CTX-M-2-producing E. coli 
have been intensively reported in Brazil, in hospital 
settings and from community and animal origins, 
including the poultry and swine production cycles 
(WARREN et al., 2008; SILVA et al., 2011) Recently, 
the CTX-M-15 enzyme has gained importance as an 
ESBL of major epidemiological importance worldwide, 
particularly due to its acquisition by a virulent strain 
belonging to the Multilocus Sequence Typing (MLST) 
group ST131 (COQUE et al., 2008; COELHO et al., 2011; 
HAWKEY; JONES, 2013). The CTX-M-15 enzyme 
was recently described in Brazilian hospitals in E. coli 
and K. pneumoniae strains (CERGOLE-NOVELLA et 
al., 2010; TOLLENTINO et al., 2011). Carbapenem 
resistance in Escherichia coli isolates is rare, but KPC-
2-producing isolates have been described in hospital 
settings in Brazil (D’ALINCOURT CARVALHO-
ASSEF et al., 2010; ALMEIDA et al., 2012). 
Some ESBL strains also present resistance to 
fluoroquinolones and trimethoprim-sulfamethoxazole. 
The emergence of fluoroquinolone-resistant extrain-
testinal pathogenic E. coli (ExPEC) has been limiting 
the utility of fluoroquinolones for treating human 
patients with urinary tract infections (UTIs), and 
delays in appropriate UTI therapy increase morbidity 
and mortality from ExPEC. In veterinary medicine, 
enrofloxacin use can select resistant phenotypes 
(PITOUT, 2012; NORDSTROM; LIU; PRICE, 2013).
Non-fermentative bacteria
Among the non-fermentative Gram-negative 
bacteria, Pseudomonas aeruginosa and Acinetobacter 
baumannii are frequently associated with nosocomial 
infections. According to a Sentry study, almost 30% 
of all lower respiratory tract infections are caused 
by Pseudomonas aeruginosa (SADER et al., 2003). 
Moreover, this bacterium is capable of causing 
sepsis and is common in burn and diabetic patients. 
The most prevalent beta-lactamase produced by 
Pseudomonas aeruginosa in Brazil is SPM-1, which 
was first described in Sao Paulo and is disseminated 
in many Brazilian regions. Other metallo-lactamases 
have been reported, such as VIM and IMP-type MBL 
(ROSSI, 2011). 
Similarly, Acinetobacter baumannii complex isolates 
have emerged as important nosocomial pathogens and 
cause ventilator-associated pneumonia, bacteremia 
and UTIs (ROSSI, 2011). The bacterial complex has 
been associated with diverse outbreaks in ICUs. 
Most carbapenem-resistant phenotype outbreaks are 
caused by OXA-23 producers. More recently, OXA-
143, a novel beta-lactamase capable of hydrolyzing 
carbapenems, has been identified in Brazilian 
hospitals (ANTONIO et al., 2011). 
 
Therapeutic options
Polymyxins (colistin)
Discovered in the 1940’s, polymyxins are cationic 
polypeptides with a high affinity for the outer 
membrane, which destabilizes LPS and results in 
outer membrane disruption. Moreover, Gram-
negative bacteria may become more susceptible 
to hydrophobic antibiotics followed by polymyxin 
exposure (ZAVASKI; GOLDANI; NATION, 2007; 
YAHAV et al., 2012). The clinical use of the only 
polymyxins (polymyxin B and colistin) available 
for this treatment was discarded due to reports 
on nephrotoxicity and neurotoxicity in the 1970s, 
and polymyxins were replaced by other antibiotics 
(BERGEN et al., 2012). Polymyxins are not active 
against Gram-positive bacteria, but they are 
effective against a variety of Gram-negative bacilli, 
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including most relevant Enterobacteriaceae and non-
fermentative species. Recently, due to the emergence 
of multiresistant pathogens, the optimal treatment 
remaining undefined and high treatment failure 
rates, polymyxins have been reintroduced into 
clinical use with the aim of treating severe “superbug” 
infections, particularly carbapenemases-producing 
Pseudomonas aeruginosa, Acinetobacter baumannii 
and KPC-producing Klebsiella pneumoniae 
(ZAVASKI, GOLDANI, NATION, 2007; LANDMAN 
et al., 2008; YAHAV et al., 2012). Polymyxin 
administration combined with imipenem, tigecycline 
or fluoroquinolone results in lower rates of treatment 
failure than monotherapy (ZAVASKI, GOLDANI, 
NATION, 2007; LEE; BURGESS, 2012), though 
resistant pathogens have emerged (CAI et al., 2012).
There are two commercial forms of colistin 
available, which differ in their fatty acid residues: 
the colistin methanesulfonate, which is less toxic and 
recommended for parenteral use; and colistin sulfate, 
which is used only for topical therapy (MORALES et 
al., 2012). In veterinary medicine, colistin sulfate is 
often used in oral preparations because it displays good 
activity against Escherichia coli and Salmonella spp. and 
presents poor absorption after oral administration and 
low rates of resistance. Considering these pathogens, 
acquired resistance to polymyxins has been attributed 
to the substitution of phosphate groups in membrane 
lipopolysaccharides. In Brazil, Escherichia coli and 
Salmonella spp. exhibiting high minimal inhibitory 
concentrations (MICs) (32 and 8 µg/ml, respectively) 
to colistin have been reported among strains isolated 
from swine (MORALES et al., 2012). 
Gram-positive bacteria
Enterococcus
Enterococci are natural inhabitants of the 
gastrointestinal microbiota of animals and may be 
released into the environment by fecal material. 
They have been detected in soil, water, plants and 
wild animals (HAMMERUM, 2012). In humans, 
Enterococcus faecalis and E. faecium can cause 
urinary tract infections, sepsis, wound infections and 
endocarditis (KWON et al., 2012). More recently, 
Enterococci have emerged as important nosocomial 
pathogens. The isolation from vulnerable patients in 
ICUs, renal and oncology units, often associated with 
intravascular catheters, has increased (BARIE, 2012). 
Enterococci infection treatment may be difficult 
because these bacteria are intrinsically resistant to 
a number of first-line antimicrobials, such as beta-
lactams and aminoglycosides (HOLLENBECK; RICE, 
2012; KWON et al., 2012). Moreover, Enterococci 
can acquire genetic determinants of resistance to 
other antimicrobials, such as quinolones, macrolides, 
tetracyclines, streptogramins and glycopeptides (CHA 
et al., 2012; BRAGA; POMBA; LOPES, 2013). In 
this context, the emergence of vancomycin-resistant 
enterococci (VRE) is a challenge during nosocomial 
infections because newer antibiotics such as linezolid, 
daptomycin and tigecycline have good in vitro activity 
against enterococcal isolates; however, their clinical 
use is limited, and resistant phenotypes have emerged 
(BARIE, 2012; BRAGA; POMBA; LOPES, 2013).
The intensive use of avoparcin has been associated with 
high vancomycin resistance rates among enterococcal 
strains (PHILLIPS et al., 2004; MARSHALL; LEVY, 
2012). Several studies from countries around the 
world have shown that vancomycin-resistant E. 
faecium persisted in animals for an extended time 
after avoparcin was banned. The most frequent 
determinants of resistance to vancomycin are the vanA 
and vanB genes. In Brazil, VRE were first reported in 
1996. The resistance alleles are located at transposon 
Tn1546 and have been currently identified in VRE 
strains (PALAZZO et al., 2011). 
The global spread of a genetic lineage of E. faecium 
inserted in clonal complex 17 (CC17) has contributed 
to change the epidemiology of enterococcal infections. 
This lineage is characterized by resistance to ampicillin 
and quinolone and harbors some virulence genes. In 
Brazil, outbreaks caused by strains belonging to CC17 
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are sporadic, and the MLST type ST114, which not 
is part of this clonal complex, is prevalent among all 
STs described. However, VREs belonging to ST50, 
ST115, ST97, ST281 and, more recently, ST412, ST448 
and ST478, all of which belong to CC17, have been 
reported in Brazilian hospitals, displaying high MICs 
to vancomycin (>256 µg/ml) (PALAZZO et al., 2011; 
SILVA et al., 2012).
As for animal origin isolates, Enterococcus faecalis 
isolated from chicken meat has shown resistance 
to tetracycline, erythromycin and streptomycin 
(FRACALANZZA et al., 2007). The reported 
prevalence of VRE in pigs and pig environments is 
highly variable around the world; thus far, resistance 
to vancomycin, teicoplanin or linezolid among 
Enterococcus faecium and Enterococcus faecalis isolated 
from animal sources in Brazil has not been reported. 
It is important to note that the Brazilian government 
has not permitted avoparcin use as a growth promoter 
in animal production since 1998. 
Staphylococcus
Staphylococcus spp. are ubiquitous environmental 
organisms that colonize the skin of humans and 
animals. These organisms cause both local and systemic 
invasive infection. Common infections involve skin, 
soft tissue, mammary glands or lymph nodes, whereas 
systemic infections cause dissemination to joints, 
bones, kidneys, liver, muscles, lungs and heart valves 
(JACKSON; NEWLAND, 2011).
The emergence of resistant Staphylococcus occurred 
quickly after the introduction of the therapeutic 
use of penicillin G, with rates of 30% in the early 
1950s, exceeding 80% resistance in US hospitals in 
the late 1950s. The production of plasmid-encoded 
penicillinases has spread the resistance, which has 
become common mainly among isolates of S. aureus. 
Currently, the global resistance rate of community-
acquired coagulase-positive and coagulase-negative 
Staphylococcus spp. exceeds 70% for penicillin G 
(benzylpenicillin). Resistance rates are also high for 
penicillin V, ampicillin, amoxicillin and carbenicillin. 
Infections are currently being combated using 
anti-staphylococcal penicillins, such as methicillin 
and oxacillin, and first- and second-generation 
cephalosporins (JACKSON; NEWLAND, 2011).
In Brazil, more than 70% of the S. aureus and S. 
epidermidis strains isolated from the community or 
the hospital environment are resistant to penicillin, 
ampicillin and amoxicillin. The frequencies of 
strains resistant to methicillin (MRSA) and oxacillin 
(ORSA) are quite variable but can vary between 30 
and 100% in nosocomial infections. However, the 
strains in the extra-hospital environment often have 
sensitivity to oxacillin (above 80%), allowing for the 
possible use of this antibiotic in community-acquired 
infections. Methicillin resistance in the extra-hospital 
environment is usually related to the patient’s 
hospitalization history and previous use of this drug 
in a hospital setting (TAVARES et al., 2000). 
Generally, staphylococci are susceptible to 
glycopeptides, but the emergence of MRSA and/or ORSA 
strains resistant to vancomycin and teicoplanin must be 
closely monitored, especially in Japan and the United 
States, where encountering these strains has become 
frequent due to selection pressure exerted by the use of 
antibiotics to combat hospital infections (TAVARES et 
al., 2000; GARCIA-ALVAREZ et al., 2012). 
Perspectives
The dissemination of resistant phenotypes is a 
great concern in human and veterinary medicine 
because it restricts therapeutic options when treating 
multiresistant strains, the so-called “superbugs.” 
Given the nature of the Brazilian economy, the ban 
of antimicrobial use in food-animal production is 
unreasonable. Rather, multidisciplinary studies aimed 
at finding the most adequate strategies for antibiotics 
use in animal and human medicine are necessary. 
Specifically in animal production, the controlled 
use of antimicrobials may lead to export advantages 
for demanding consumer markets, such European 
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countries, which ban the use of growth promoters. 
Broad-spectrum antimicrobials favor resistance 
development because they disrupt competing 
susceptible microflora, and narrow-spectrum drugs are 
more appropriate. In hospital settings, antimicrobial 
rotation, guided by resistance surveillance systems, 
has yielded good results (BROWN; NATHWANI, 
2005). Moreover, combined therapy with synergic 
drugs may be an alternative when dealing with 
multiresistant isolates. Sanitary measures to avoid 
bacterial dissemination and to prevent infection are 
also required, as is the education of veterinarians, 
farmers, food producers and consumers about the 
rationale for the prudent use of antimicrobials, disease 
prevention and prevention of zoonotic infections in 
humans and animals (LANDERS et al., 2012).
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